Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Fojo

Showing results (21-30 of 180) with videos related to

Pageof 18
Sort By:
The Journal of Clinical Endocrinology and Metabolism|February 7, 2001
Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cellsM Kitazono, Y Chuman, T Aikou, et al.
Current Drug Targets|May 12, 2004
Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attackW D Stein, S E Bates, T Fojo
Japanese Journal of Cancer Research : Gann|September 27, 2001
Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressureY Matsumoto, H Takano, S Nagao, et al.
Leukemia & Lymphoma|March 14, 1998
The role of MDR-1 in refractory lymphomaV Sandor, W Wilson, T Fojo, et al.
Archives of Biochemistry and Biophysics|July 15, 1983
Effects of acetylation and guanidination on alkaline conformations of chymotrypsinA T Fojo, P L Whitney, W M Awad
Hospital Practice (Office Ed.)|April 15, 1990
Multidrug resistance due to P-glycoproteinR K Burt, A T Fojo, S S Thorgeirsson
The Journal of Clinical Investigation|February 23, 2000
Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugsM V Blagosklonny, R Robey, S Bates, et al.
Biochemical and Biophysical Research Communications|March 26, 1998
Like p53, the proliferation-associated protein p120 accumulates in human cancer cells following exposure to anticancer drugsM V Blagosklonny, A Iglesias, Z Zhan, et al.
Oncogene|July 6, 2001
Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicityP Giannakakou, R Robey, T Fojo, et al.
The Lancet. Respiratory Medicine|December 20, 2016
Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysisEmily A Kendall, Anthony T Fojo, David W Dowdy
Pageof 18

Showing results (21-30 of 180) with videos related to

Sort By:
Pageof 18
The Journal of Clinical Endocrinology and Metabolism|February 7, 2001
Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cellsM Kitazono, Y Chuman, T Aikou, et al.
Current Drug Targets|May 12, 2004
Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attackW D Stein, S E Bates, T Fojo
Japanese Journal of Cancer Research : Gann|September 27, 2001
Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressureY Matsumoto, H Takano, S Nagao, et al.
Leukemia & Lymphoma|March 14, 1998
The role of MDR-1 in refractory lymphomaV Sandor, W Wilson, T Fojo, et al.
Archives of Biochemistry and Biophysics|July 15, 1983
Effects of acetylation and guanidination on alkaline conformations of chymotrypsinA T Fojo, P L Whitney, W M Awad
Hospital Practice (Office Ed.)|April 15, 1990
Multidrug resistance due to P-glycoproteinR K Burt, A T Fojo, S S Thorgeirsson
The Journal of Clinical Investigation|February 23, 2000
Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugsM V Blagosklonny, R Robey, S Bates, et al.
Biochemical and Biophysical Research Communications|March 26, 1998
Like p53, the proliferation-associated protein p120 accumulates in human cancer cells following exposure to anticancer drugsM V Blagosklonny, A Iglesias, Z Zhan, et al.
Oncogene|July 6, 2001
Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicityP Giannakakou, R Robey, T Fojo, et al.
The Lancet. Respiratory Medicine|December 20, 2016
Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysisEmily A Kendall, Anthony T Fojo, David W Dowdy
Pageof 18